News Category
Regentis Biomaterials' receipt of a Japanese Notice of Allowance for its GelrinC manufacturing process strengthens its IP portfolio and supports upcom...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize its BiTAC platform, potentially improving target validation and reducing development r...
VERAXA Biotech's collaboration with Ardigen aims to use AI to identify optimal dual-target combinations, potentially reviving abandoned therapies and ...
The American Heart Association is accepting applications for its 2026 Health Tech Competition, aiming to close the gap between promising health techno...
Scientists have identified a protein on glioblastoma cells that could be targeted to make the cancer more vulnerable to existing treatments, offering ...
NanoViricides is set to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more practical treatment opti...
Helus Pharma appoints Regina Donohue as Chief People Officer and Dr. Suresh Durgam to its Scientific Advisory Board, strengthening its organizational ...
The 20th Annual Sickle Cell Disease Educational Summit, hosted by Cayenne Wellness Center, celebrates two decades of progress while highlighting new t...
Helix BioPharma's appointment of Dr. Markus Loeffler as CMO is a strategic move to accelerate its oncology pipeline, including the upcoming Phase Ib/I...
Quantum BioPharma reports significant cost reductions and FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment for progressive multip...
Regentis Biomaterials is simultaneously advancing its GelrinC cartilage repair implant through US Phase III trials and European commercial rollout, ai...
Alpha Cognition's second-quarter results show accelerating ZUNVEYL demand and improved commercial execution, positioning the company for growth despit...
Two $200,000 grants will fund research into the lung microbiome's role in cancer development and mechanisms of drug resistance, aiming to improve earl...
PX1 Research's new seven-stage testing protocol ensures 99%+ purity for research peptides, offering batch-level COA documentation and same-day shippin...
A comprehensive review in World Journal of Pediatric Surgery synthesizes current evidence on surgical management of necrotizing enterocolitis, emphasi...
Onco-Innovations is progressing its precision oncology candidate ONC010 through IND-enabling activities, positioning itself in the expanding field of ...
Regentis Biomaterials advances its GelrinC hydrogel implant with European approval for a solvent-free manufacturing process, targeting a multi-billion...
Researchers at the University of Manchester discovered that a small group of immune cells, often overlooked, are crucial for mobilizing and sustaining...
Quantum BioPharma reported reduced Q2 expenses and FDA approval to proceed with a Phase 2 trial for Lucid-MS, a potential treatment for progressive mu...
Regentis Biomaterials is simultaneously advancing its cartilage repair product GelrinC through US clinical trials and European commercialization, with...
Lantern Pharma's Q2 2026 results highlight progress in its AI-driven oncology pipeline, including promising LP-300 trial data and the establishment of...
Helus Pharma reports enrollment completion in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expected i...
DM Clinical Research marks its 20th anniversary, highlighting its growth into a leading clinical research network and its ongoing commitment to broade...
NeOnc Technologies reported positive Phase 2a data for NEO100 in recurrent brain cancer, with significant survival benefits and regulatory clarity, po...
PX1 Research expands its peptide catalog with domestically manufactured retatrutide and tirzepatide, each batch verified for 99%+ purity via HPLC, sup...
Quantum BioPharma's Lucid-MS focuses on inhibiting myelin degradation to address progression independent of relapse activity, a key driver of long-ter...
GeoVax announces its preparedness to contribute its MVA-based hemorrhagic fever vaccine expertise and candidates to the global response against the ra...
Global drugmakers are investing approximately $500 billion in the US to avoid planned tariffs on drug imports, with major companies like Amgen, AbbVie...
Nutriband CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit, highlighting the company's AVERSA abuse-deterrent technology and ...
Quantum BioPharma's multiple sclerosis candidate Lucid-MS has received FDA clearance to enter Phase 2 trials, marking a significant step toward a pote...
PX1 Research introduces cGMP-manufactured sublingual peptide strips for research, offering needle-free alternatives with verified purity, impacting me...
PX1 Research expands domestic manufacturing with cGMP quality control and HPLC purity verification, ensuring 99%+ purity on all research peptides, whi...
NanoViricides received approval to conduct a Phase II trial of its oral antiviral NV-387 against the ongoing Ebola outbreak in the DRC, potentially of...
New research from the University of Virginia suggests focused ultrasound could enhance drug delivery to deadly brain tumors, potentially improving tre...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in prostate and triple-negative breast can...
Quantum BioPharma's FDA approval to advance Lucid-MS into Phase 2 trials marks a pivotal step for a novel neuroprotective approach that could differen...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, fueled by TONMYA's market traction, signaling a significant commercial milestone and r...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, propelled by TONMYA's market uptake, signaling a successful commercial launch for the ...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA sales, marking significant commercial progress for the newly approved...
A new narrative review provides a comprehensive framework for risk-adapted neuroblastoma care, emphasizing molecular and clinical factors to tailor tr...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration technology through clinical trials and regulatory pathways, positioning it to ...
Quantum BioPharma is progressing its investigational MS therapy Lucid-MS and its supplement unbuzzd, addressing both myelin repair and alcohol metabol...
Quantum BioPharma is developing a two-pronged approach to neurological health, targeting myelin repair in multiple sclerosis and alcohol metabolism, w...
VERAXA Biotech's proprietary BiTAC platform positions it for potential partnerships and licensing deals in the high-value ADC and T-cell engager marke...
A case in Spain where a patient's neurocysticercosis mimicked brain cancer highlights the diagnostic challenges and the urgent need for better treatme...
Lantern Pharma's upcoming Q2 2026 earnings webcast will detail progress on its AI platforms and clinical pipeline, underscoring the company's strategi...
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its patent portfolio, undersco...
A new liquid biopsy offers a simple way to forecast which advanced lung cancer patients will benefit from immunotherapy, potentially aiding drug devel...
